Clinical Trials Directory

Trials / Completed

CompletedNCT00490945

Safety and Efficacy of VEC-162 on Circadian Rhythm in Healthy Adult Volunteers

A Randomized, Double-blind, Placebo-controlled, Multi-center Study of the Effects of VEC-162 on Circadian Rhythm in Healthy Subjects

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
45 (actual)
Sponsor
Vanda Pharmaceuticals · Industry
Sex
All
Age
18 Years – 50 Years
Healthy volunteers
Accepted

Summary

The purpose of this study is to assess the safety and efficacy of VEC-162 compared to matching placebo on circadian phase shift and sleep parameters.

Conditions

Interventions

TypeNameDescription
DRUGVEC-162

Timeline

Start date
2004-07-01
Primary completion
2005-03-01
Completion
2005-03-01
First posted
2007-06-25
Last updated
2014-08-26
Results posted
2014-08-26

Locations

2 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT00490945. Inclusion in this directory is not an endorsement.